U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure
April 17, 2024 08:00 ET
|
Kaléo
Richmond, Virginia, April 17, 2024 (GLOBE NEWSWIRE) -- Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development...
Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids
September 21, 2022 08:00 ET
|
Kaléo
Richmond, VA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kaléo, a privately held commercial-stage U.S. pharmaceutical company, today announced the execution of the first contract with the U.S. Department of...
Kaléo Announces Executive Appointments and New Government Business Unit
August 11, 2022 08:25 ET
|
Kaléo
Richmond, VA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products for certain...
Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense
September 25, 2019 16:15 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded approximately $20 million to develop and manufacture an...
Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents
February 28, 2019 16:45 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with the...